Neuroendocrine Carcinoma Global Market Report 2025

Description

Neuroendocrine carcinoma (NEC) is a rare and aggressive cancer that arises from neuroendocrine cells, which possess characteristics of both nerve cells and hormone-producing cells. It is diagnosed and treated to manage tumors that can develop in various organs, including the lungs, pancreas, and gastrointestinal tract, often requiring a combination of surgery, chemotherapy, and targeted therapies.

The primary types of neuroendocrine carcinoma include gastroenteropancreatic neuroendocrine tumors, carcinoid tumors, pheochromocytoma, and medullary thyroid carcinoma. Gastroenteropancreatic neuroendocrine tumors are rare malignancies that originate from neuroendocrine cells in the gastrointestinal tract or pancreas. Diagnosis involves various tools such as imaging, biopsy, and serology, while treatment options include chemotherapy, radiotherapy, surgery, and others. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, serving end users such as hospitals, clinics, oncology centers, and ambulatory surgery centers.

The neuroendocrine carcinoma market research report is one of a series of new reports from The Business Research Company that provides neuroendocrine carcinoma market statistics, including the neuroendocrine carcinoma industry global market size, regional shares, competitors with the neuroendocrine carcinoma market share, detailed neuroendocrine carcinoma market segments, market trends, and opportunities, and any further data you may need to thrive in the neuroendocrine carcinoma industry. This neuroendocrine carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neuroendocrine carcinoma market size has grown strongly in recent years. It will grow from $1.63 billion in 2024 to $1.76 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period was driven by the expansion of the imaging sector, a rising incidence of neuroendocrine tumors, increasing investments, government initiatives, and growing demand for treatments for neuroendocrine tumors.

The neuroendocrine carcinoma market size is expected to see strong growth in the next few years. It will grow to $2.33 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period is expected to be driven by the rising incidence of cancer, an increasing rate of product approvals, greater adoption of advanced diagnostic imaging methods, the expansion of targeted therapies, and improved diagnosis and treatment options. Key trends include advancements in diagnostic and imaging technologies, the development of targeted treatment approaches, innovations in neuroendocrine tumor management, and continued progress in targeted therapies and immunotherapies.

The expansion of targeted therapies is expected to drive the growth of the neuroendocrine carcinoma market. Targeted therapies are designed to disrupt the molecular processes or genetic mutations responsible for disease progression, particularly in cancer. The increasing demand for targeted therapies is fueled by their precision in addressing specific genetic mutations, advancements in personalized medicine, and improved patient outcomes with fewer side effects. Neuroendocrine carcinoma research facilitates the development of targeted therapies that align with the tumor's genetic and biochemical profiles, enhancing treatment accuracy and effectiveness. For instance, in July 2023, the American Society of Gene & Cell Therapy (ASGCT) and Citeline reported that the number of gene therapies in Phase II clinical trials increased by 5%, from 247 at the end of Q1 2023 to 260 by the end of Q2 2023. This growth underscores the increasing focus on targeted treatment strategies, driving the neuroendocrine carcinoma market.

Leading companies in the neuroendocrine carcinoma market are focusing on advancements in targeted radiopharmaceutical therapy to enhance treatment precision and improve patient outcomes. Targeted radiopharmaceutical therapy uses radioactive molecules that specifically deliver radiation to cancer cells while minimizing damage to healthy tissue. For example, in September 2024, Abdera Therapeutics Inc., a Canada-based biotechnology company, received an orphan drug designation from the FDA for ABD-147 for the treatment of neuroendocrine carcinoma. ABD-147 is designed to selectively target tumors expressing the DLL3 protein, which is commonly upregulated in aggressive neuroendocrine cancers such as small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). This designation provides significant benefits, including tax credits for clinical trials and potential market exclusivity, positioning ABD-147 as a promising treatment option in the field of oncology.

In February 2024, Bristol-Myers Squibb Company, a US-based pharmaceutical company, acquired RayzeBio, Inc. for $4.1 billion. This acquisition aims to strengthen Bristol-Myers Squibb's oncology pipeline, particularly in neuroendocrine tumors and other difficult-to-treat cancers, by leveraging RayzeBio's expertise in targeted therapies and innovative drug development. RayzeBio Inc. is a US-based company specializing in the treatment of gastroenteropancreatic neuroendocrine tumors.

Major players in the neuroendocrine carcinoma market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Boehringer Ingelheim GmbH, Exelixis Inc., Lantheus Holdings Inc., HUTCHMED Limited, Dana-Farber Cancer Institute Inc., Abdera Therapeutics Inc., Orano Med S.A, Eckert & Ziegler Radiopharma GmbH, Callisto Pharmaceuticals Inc., RadioMedix Inc., Clarity Pharmaceuticals Limited, Delcath Systems Inc., Provectus Biopharmaceuticals Inc.

North America was the largest region in the neuroendocrine carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuroendocrine carcinoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neuroendocrine carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neuroendocrine carcinoma market consists of revenues earned by entities by providing services such as hormonal symptom management, long-term care plans, pain management, immunotherapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuroendocrine carcinoma market also consists of sales of products including somatostatin analogs, positron emission tomography (PET) scanners, needles and equipment, infusion pumps, and drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neuroendocrine Carcinoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neuroendocrine carcinoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neuroendocrine carcinoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neuroendocrine carcinoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Gastroenteropancreatic Neuroendocrine Tumors; Carcinoid Tumors; Pheochromocytoma; Medullary Thyroid Carcinoma
2) By Diagnostic Tools: Imaging; Biopsy; Serology
3) By Treatment: Chemotherapy; Radiotherapy; Surgery; Other Treatments
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End-User: Hospitals; Clinics; Oncology Centers; Ambulatory Surgery Centers
Subsegments:
1) By Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Pancreatic Neuroendocrine Tumors (pNETs); Small Intestinal Neuroendocrine Tumors; Gastric Neuroendocrine Tumors; Colorectal Neuroendocrine Tumors
2) By Carcinoid Tumors: Pulmonary Carcinoid Tumors; Gastrointestinal Carcinoid Tumors
3) By Pheochromocytoma: Adrenal Pheochromocytoma; Extra-Adrenal Paraganglioma
4) By Medullary Thyroid Carcinoma: Sporadic Medullary Thyroid Carcinoma; Hereditary Medullary Thyroid Carcinoma (MEN2-Associated)
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Bristol-Myers Squibb Company; AstraZeneca plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r34095

1. Executive Summary

2. Neuroendocrine Carcinoma Market Characteristics

3. Neuroendocrine Carcinoma Market Trends And Strategies

4. Neuroendocrine Carcinoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Neuroendocrine Carcinoma Growth Analysis And Strategic Analysis Framework

5.1. Global Neuroendocrine Carcinoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Neuroendocrine Carcinoma Market Growth Rate Analysis
5.4. Global Neuroendocrine Carcinoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Neuroendocrine Carcinoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Neuroendocrine Carcinoma Total Addressable Market (TAM)

6. Neuroendocrine Carcinoma Market Segmentation

6.1. Global Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gastroenteropancreatic Neuroendocrine Tumors
Carcinoid Tumors
Pheochromocytoma
Medullary Thyroid Carcinoma
6.2. Global Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Imaging
Biopsy
Serology
6.3. Global Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Radiotherapy
Surgery
Other Treatments
6.4. Global Neuroendocrine Carcinoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.5. Global Neuroendocrine Carcinoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Oncology Centers
Ambulatory Surgery Centers
6.6. Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pancreatic Neuroendocrine Tumors (pNETs)
Small Intestinal Neuroendocrine Tumors
Gastric Neuroendocrine Tumors
Colorectal Neuroendocrine Tumors
6.7. Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Carcinoid Tumors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pulmonary Carcinoid Tumors
Gastrointestinal Carcinoid Tumors
6.8. Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Pheochromocytoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adrenal Pheochromocytoma
Extra-Adrenal Paraganglioma
6.9. Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Medullary Thyroid Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Sporadic Medullary Thyroid Carcinoma
Hereditary Medullary Thyroid Carcinoma (MEN2-Associated)

7. Neuroendocrine Carcinoma Market Regional And Country Analysis

7.1. Global Neuroendocrine Carcinoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Neuroendocrine Carcinoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neuroendocrine Carcinoma Market

8.1. Asia-Pacific Neuroendocrine Carcinoma Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neuroendocrine Carcinoma Market

9.1. China Neuroendocrine Carcinoma Market Overview
9.2. China Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neuroendocrine Carcinoma Market

10.1. India Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neuroendocrine Carcinoma Market

11.1. Japan Neuroendocrine Carcinoma Market Overview
11.2. Japan Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neuroendocrine Carcinoma Market

12.1. Australia Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neuroendocrine Carcinoma Market

13.1. Indonesia Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neuroendocrine Carcinoma Market

14.1. South Korea Neuroendocrine Carcinoma Market Overview
14.2. South Korea Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neuroendocrine Carcinoma Market

15.1. Western Europe Neuroendocrine Carcinoma Market Overview
15.2. Western Europe Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neuroendocrine Carcinoma Market

16.1. UK Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neuroendocrine Carcinoma Market

17.1. Germany Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neuroendocrine Carcinoma Market

18.1. France Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neuroendocrine Carcinoma Market

19.1. Italy Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neuroendocrine Carcinoma Market

20.1. Spain Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neuroendocrine Carcinoma Market

21.1. Eastern Europe Neuroendocrine Carcinoma Market Overview
21.2. Eastern Europe Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neuroendocrine Carcinoma Market

22.1. Russia Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neuroendocrine Carcinoma Market

23.1. North America Neuroendocrine Carcinoma Market Overview
23.2. North America Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neuroendocrine Carcinoma Market

24.1. USA Neuroendocrine Carcinoma Market Overview
24.2. USA Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neuroendocrine Carcinoma Market

25.1. Canada Neuroendocrine Carcinoma Market Overview
25.2. Canada Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neuroendocrine Carcinoma Market

26.1. South America Neuroendocrine Carcinoma Market Overview
26.2. South America Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neuroendocrine Carcinoma Market

27.1. Brazil Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neuroendocrine Carcinoma Market

28.1. Middle East Neuroendocrine Carcinoma Market Overview
28.2. Middle East Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neuroendocrine Carcinoma Market

29.1. Africa Neuroendocrine Carcinoma Market Overview
29.2. Africa Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neuroendocrine Carcinoma Market Competitive Landscape And Company Profiles

30.1. Neuroendocrine Carcinoma Market Competitive Landscape
30.2. Neuroendocrine Carcinoma Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Neuroendocrine Carcinoma Market Other Major And Innovative Companies

31.1. Novartis AG
31.2. Amgen Inc.
31.3. Boehringer Ingelheim GmbH
31.4. Exelixis Inc.
31.5. Lantheus Holdings Inc.
31.6. HUTCHMED Limited
31.7. Dana-Farber Cancer Institute Inc.
31.8. Abdera Therapeutics Inc.
31.9. Orano Med S.A
31.10. Eckert & Ziegler Radiopharma GmbH
31.11. Callisto Pharmaceuticals Inc.
31.12. RadioMedix Inc.
31.13. Clarity Pharmaceuticals Limited
31.14. Delcath Systems Inc.
31.15. Provectus Biopharmaceuticals Inc.

32. Global Neuroendocrine Carcinoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neuroendocrine Carcinoma Market

34. Recent Developments In The Neuroendocrine Carcinoma Market

35. Neuroendocrine Carcinoma Market High Potential Countries, Segments and Strategies

35.1 Neuroendocrine Carcinoma Market In 2029 - Countries Offering Most New Opportunities
35.2 Neuroendocrine Carcinoma Market In 2029 - Segments Offering Most New Opportunities
35.3 Neuroendocrine Carcinoma Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer